US FDA Contradicted The Advice Of Pfizer On Retaking Covid-19 Drug


An official of the Food and Drug Administration (FDA) of the United States said, there is no evidence that, a second course of Paxlovid, covid-19 drug of Pfizer, is going to be helping the corona virus patients whose symptoms to return after an initial course of the antiviral drug.

The virologists and doctors have been struggling to understand a number of patient reports of the viral rebounds after the completion of a five-day course of the novel corona virus treatment.

Albert Bourla, chief executive officer of Pfizer said, in cases where the virus levels have been rebounded, then the doctors can give a second course like the people do with the antibiotics and some of the physicians have also suggested a longer course of Paxlovid might be preventing the symptoms from returning.

The Center for Drug Evaluation and Research of US FDA said, no data has been supporting a longer course of treatment for the purpose of treating the relapse and there has been no evidence of benefit at this time for either repeat dosing crouse of the treatment, and they are also continuing to review the data from the clinical trials and is also going to provide additional information as it is becoming available.

READ  US FDA Approves Incyte’s Skin Cancer Therapy

The analysis of the previous clinical data has shown that, around 1 percent or 2 percent of the people had positive PCR tests followed by course of Paxlovid course although some people, who had received a placebo drug has also experienced a viral rebound.